Erschienen in:
Open Access
01.12.2012 | Poster presentation
AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
verfasst von:
Kunihiro Yamaoka, Satoshi Kubo, Koshiro Sonomoto, Keisuke Maeshima, Yoshiya Tanaka
Erschienen in:
Arthritis Research & Therapy
|
Sonderheft 1/2012
Einloggen, um Zugang zu erhalten
Excerpt
Tofacitinib, targeting Janus kiase (JAK) has gained attention as anorally available new disease modifying anti-rheumatic drug with high clinical efficacy against rheumatoid arthritis (RA). While the clinical trial has progressed and the wide usage of tofacitinib is conceivable in the near future, the precise mechanism of action in RA patients remains to be solved. …